Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06996626 · ClinicalTrials.gov registry record · NA
Real-time NOMA Evaluation
A NA study of Critical Illness, sponsored by David T Huang.
- Recruiting
- Registry status
- NA
- Development phase
- 3,000
- Enrollment target
- 2
- Study locations
NCT06996626: Recruiting NA study of Critical Illness, sponsored by David T Huang.
NCT06996626 is a NA study of Critical Illness that is actively recruiting participants, run by David T Huang. The registered enrollment target is 3,000 participants, roughly in line with the 3,105-participant average among 91 other Critical Illness trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06996626, a NA study of Critical Illness, is actively recruiting participants, sponsored by David T Huang.
- RECRUITING
- Registry status
- NA
- Development phase
- 3,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
Alerts related to outlier clinician behavior are generated in real-time by an intelligent system continuously scraping EHR (electronic health record) data. These alerts are passed to the bedside and their potential impact on bedside clinical behavior is evaluated.
Primary Outcome
The primary outcome compares the proportion of alerts that lead to documented clinical actions when revealed to treating ICU clinicians versus when not revealed. Alerts are generated by a decision support system and reviewed daily by ICU study clinicians. On average, 30 alerts are reviewed per ICU per day, with approximately 5 alerts revealed to the treating clinicians. The analysis uses a stepped wedge design with ICU beds as the unit of analysis, where each ICU acts as its own control. The out
Conditions Studied
Interventions
- DEVICE Revealed Alerts
- DEVICE Unrevealed Alerts
Study Locations (2)
Pennsylvania
- UPMC Montefiore - Pittsburgh
- UPMC Presbyterian - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT06996626 shows while recruiting
NCT06996626 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 3,105-participant average among 91 other Critical Illness trials with a reported enrollment target.
The record links to 1 condition, with Critical Illness appearing as the primary indexed condition, and to 2 interventions - of which Revealed Alerts is the first listed.
NCT06996626 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06996626 about?
NCT06996626 is a clinical study titled "Real-time NOMA Evaluation". Alerts related to outlier clinician behavior are generated in real-time by an intelligent system continuously scraping EHR (electronic health record) data. These alerts are passed to the bedside and their potential impact on bedside clinical behavior is evaluated.
What is the current status of trial NCT06996626?
This trial is currently recruiting. It is a NA study. The enrollment target is 3,000 participants. The study started on 2025-06-23. Estimated completion is 2027-06-30.
What conditions does trial NCT06996626 study?
This clinical trial studies the following conditions: Critical Illness.
What interventions are being tested in trial NCT06996626?
The interventions under investigation include: Revealed Alerts (DEVICE), Unrevealed Alerts (DEVICE).
Who is sponsoring clinical trial NCT06996626?
This trial is sponsored by David T Huang, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06996626 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Critical Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06996626's enrollment target sits among peer trials
3,000 7th of 91 higher than 84 of 91 other Critical Illness trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Critical Illness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
RECRUITING · NA
-
Improving Needs Among Older Adults
RECRUITING · NA
-
The Family Perspectives Project Pilot Trial
RECRUITING · NA
-
12-hour Time Limited Feeding in Critical Care
RECRUITING · NA
-
PUSH-IT Continuing Enteral Feeds for Tracheostomy
RECRUITING · NA
-
Reestablishing Sleep and Circadian Alignment in Medical Intensive Care Unit (MICU) Patients Via a Mechanistic RCT of an Sleep Chronobundle
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI